Cullinan Therapeutics, Inc. CGEM
At closeNov 4, 2026, 6:41 PM EST
After hours · Nov 4, 6:41 PM ET
- YTD
- +20.68%
- 1 year
- +68.78%
- Market cap
- 767.61M
- EPS (ttm)
- -2.46
- Shares out
- 64.35M
- Forward P/E
- -6.30
- YTD return
- +20.68%
- 1-year return
- +68.78%
- Volume
- 2.20M
- Avg volume
- 905.59K
- Open
- 15.99
- Previous close
- 15.75
- Day's range
- 11.92 – 16.29
- 52-week range
- 7.19 – 22.95
- Beta
- -0.04
- Analysts
- Strong Buy
- Price target
- 34.60 (+177.0%)
- Earnings date
- Nov 5, 2026
2Y -3.46 (-21.65%)
Key statistics
- Enterprise value
- 622.56M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.11
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -89.23M
- Total cash
- 334.54M
- Total debt
- 2.07M
- Return on equity
- -50.30%
- Short % of float
- 16.53%
- 50-day average
- 18.28
- 200-day average
- 15.74
Analyst view
Consensus: strong buy
- Target (low)
- 27.00
- Target (mean)
- 34.60
- Target (high)
- 42.00
- Strong buy1
- Buy11
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.83991.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.84349 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.79931 | -0.81 | -0.01 | -1.34% |
| May 7, 2026 | Mar 31, 2026 | -0.83588 | -0.75 | +0.09 | +10.27% |
| Mar 10, 2026 | Dec 31, 2025 | -0.80 | -0.77 | +0.03 | +3.75% |
| Nov 6, 2025 | Sep 30, 2025 | -0.95 | -0.77 | +0.18 | +18.95% |
| Aug 7, 2025 | Jun 30, 2025 | -0.83 | -1.07 | -0.24 | -28.92% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | BTIG | main | Buy | Buy |
| Oct 19, 2026 | BTIG | reit | Buy | Buy |
| Oct 2, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 25, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 25, 2026 | BTIG | reit | Buy | Buy |
| Sep 14, 2026 | BTIG | main | Buy | Buy |
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cullinantherapeutics.com
News
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting 
Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect? 
3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead 
BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $41 
Cullinan Therapeutics Gets FDA And Australian Therapeutic Goods Administration Clearance To Initiate Its Global Phase 1b/2a Clinical Trial In Adults With Relapsing And Refractory ITP And Warm Autoimmune Hemolytic Anemia 
Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA 
BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target 
Taiho Oncology and Cullinan Therapeutics Say Data From Cohort C Of Phase 2 REZILIENT2 Trial Of Zipalertinib For Locally Advanced Or Metastatic Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Or Uncommon EGFR Mutations and Active CNS Metastases Shows Intracranial Objective Response Rate Of 30.2% In 43 Evaluable Patients 
Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases 
Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia
Your note
Sign in to keep a note on CGEM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AHMED NADIM | Chief Executive Officer | Sale | Feb 23, 2026 | 390,803 |
| FENTON MARY KAY | Chief Financial Officer | Stock Award(Grant) | Jun 29, 2026 | 127,921 |
| JONES JEFFREY ALAN | Officer | Sale | Feb 23, 2026 | 159,968 |
| LYNX1 CAPITAL MANAGEMENT LP | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 27, 2025 | 0 |
| MICHAELSON JENNIFER | Officer | Sale | Sep 7, 2026 | 158,844 |
| SAVILL CORRINE | Officer | Stock Award(Grant) | Feb 18, 2025 | 240,990 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MPM Bioimpact LLC | 15.12% | 9,731,341 | 151.42M | Jun 29, 2026 |
| Lynx1 Capital Management Lp | 13.93% | 8,963,500 | 139.47M | Jun 29, 2026 |
| BVF Inc. | 8.94% | 5,750,683 | 89.48M | Jun 29, 2026 |
| Blackrock Inc. | 8.13% | 5,232,766 | 81.42M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 5.95% | 3,825,950 | 59.53M | Jun 29, 2026 |
| State Street Corporation | 5.70% | 3,668,627 | 57.08M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.00% | 1,929,766 | 30.03M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.44% | 1,570,216 | 24.43M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.91% | 1,226,294 | 19.08M | Sep 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.58% | 1,019,356 | 15.86M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.03% | 660,987 | 10.28M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.97% | 621,218 | 9.67M | Jun 29, 2026 |